Innoviva, Inc.
INVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Innoviva, Inc. (INVA) is listed under Biotechnology. The $1.54B market capitalization puts INVA squarely in small-cap range for its industry. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.54B
Beta
0.33
P/E (TTM)
4.95
P/E (Fwd)
9.65
EPS (TTM)
$4.31
EPS (Fwd)
$2.21
ROE
36.7%
ROA
7.0%
Cash
$579.1M
Total Debt
$331.2M
Free CF
$110.3M
52W Change
5.7%
Annual Financials
Cash vs Debt
Where INVA stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, INVA finished 5.37% below its 150-day moving average ($22.15) and 3.41% below its 200-day moving average ($21.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INVA overbought or oversold?
At the August 18, 2026 close, INVA's RSI(14) was 38.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $579.1M in cash comfortably exceeding the $331.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $110.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 36.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $331.3M (2022) to $411.3M (2025), reflecting a 24% increase over the period.
INVA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Innoviva, Inc.'s trajectory.